Conray 43 side effects by duration, gender and age - a phase IV clinical study of FDA data

Summary:

Side effects are reported by people who take Conray 43. Common side effects include pruritus among females and cardio-respiratory arrest among males.

The phase IV clinical study is created by eHealthMe based on 17 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 14, 2022

17 people who take Conray 43 and have side effects are studied.


What is Conray 43?

Conray 43 has active ingredients of iothalamate meglumine. eHealthMe is studying from 17 Conray 43 users for its effectiveness, alternative drugs and more.

Number of Conray 43 reports submitted per year:

Conray 43 side effects.

Conray 43 side effects by time on the drug*:

< 1 month:

  1. Asthenia (weakness)
  2. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Pruritus (severe itching of the skin)
  2. Anaphylactic reaction (serious allergic reaction)
  3. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
  4. Coma (state of unconsciousness lasting more than six hours)
  5. Drug maladministration
  6. Flushing (the warm, red condition of human skin)
  7. Injection site extravasation (flow of (blood or lymph) from injection site)
  8. Nausea (feeling of having an urge to vomit)
  9. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

Conray 43 side effects by gender *:

female:

  1. Pruritus (severe itching of the skin)
  2. Anaphylactic reaction (serious allergic reaction)
  3. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
  4. Asthenia (weakness)
  5. Drug maladministration
  6. Flushing (the warm, red condition of human skin)

male:

  1. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  2. Coma (state of unconsciousness lasting more than six hours)
  3. Injection site extravasation (flow of (blood or lymph) from injection site)
  4. Nausea (feeling of having an urge to vomit)
  5. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

Conray 43 side effects by age (0-1 to 60+) *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Nausea (feeling of having an urge to vomit)
  2. Anaphylactic reaction (serious allergic reaction)
  3. Flushing (the warm, red condition of human skin)

40-49:

n/a

50-59:

  1. Pruritus (severe itching of the skin)

60+:

  1. Asthenia (weakness)
  2. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  3. Coma (state of unconsciousness lasting more than six hours)
  4. Drug maladministration
  5. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

* Approximation only. Some reports may have incomplete information.

Do you take Conray 43?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



How the study uses the data?

The study is based on iothalamate meglumine (the active ingredients of Conray 43) and Conray 43 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies

Alternative drugs to, pros and cons of Conray 43:

All Conray 43 side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: